New VFC & VFAAR Vaccine Available
Priorix

Priorix (Measles, Mumps, and Rubella Vaccine, Live, CVX code: **03**, CPT code: **90707**) is now available through the Vaccines for Children (VFC) and Vaccines for Adults at Risk (VFAAR) programs. **Priorix is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.**

On June 6th, 2022, Priorix was licensed by the Food and Drug Administration. On June 23, 2022, the Advisory Committee on Immunization Practices (ACIP) unanimously recommended Priorix as an option to prevent measles, mumps, and rubella according to the existing recommended schedules and for off-label uses (i.e., indications not included in the package insert).

Recommendations For Use

Eligible Groups for Receipt of VFC and VFAAR Supplies of Priorix

VFC supplies of Priorix may be given to VFC-eligible individuals, 0 through 18 years of age. VFAAR supplies of Priorix may be given to VFAAR eligible patients,19 years of age and up, based on underlying medical conditions or other risk factors and history of vaccination.

Clinical Guidance

Dosing schedule

Priorix is a two-dose series. Administer a first dose of Priorix at 12 through 15 months of age and a second doses at 4 through 6 years of age. If Priorix is not administered according to this schedule and 2 doses of measles-, mumps- and rubella-virus (MMR) vaccine are recommended for an individual, there should be a minimum of 4 weeks (28 days) between the first and second dose. Priorix may be administered as a second dose to individuals who have received a first dose of another measles, mumps and rubella virus-containing vaccine. For all recommendations, MMR II and Priorix can be used interchangeably. Either vaccine may be administered in any situation in which an MMR virus–containing vaccine is indicated. Interruption of the vaccination schedule does not require reinstitution of the entire series or the addition of extra doses.

Coadministration with other vaccines

Priox can be administered concomitantly, at different anatomic sites, with other routine childhood vaccines. Concomitant administration of Priorix with other live and non-live vaccines has been studied; results indicated no safety concerns or evidence for interference in the immune response to either. Additional live virus vaccines not administered on the same day should be separated by ≥4 weeks (28 days).

Off-label uses

Both M-M-R II and Priorix can be administered to infants aged 6–11 months who will travel or live abroad or during measles outbreaks and as a third dose of MMR in persons previously vaccinated with 2 doses of a mumps virus–containing vaccine who are identified by public health authorities as being part of a group or population at increased risk for acquiring mumps because of an outbreak. In addition, Priorix is indicated for off-label use for measles postexposure prophylaxis.

Philadelphia Department of Public Health - Division of Disease Control - Immunization Program
1101 Market St. Floor 12, Philadelphia, PA, 19107 | **vax.phila.gov** | **vaccines@phila.gov** | December 2022

Department of Public Health
CITY OF PHILADELPHIA

New VFC & VFAAR Vaccine Available
Priorix

Licensed Dosing Schedule

MMR vaccine is recommended routinely for all children at age 12 through 15 months, with a second dose at age 4 through 6 years. The second dose of MMR can be given as early as 4 weeks (28 days) after the first dose and be counted as a valid dose if both doses were given after the child's first birthday. The second dose is not a booster, but rather is intended to produce immunity in the small number of people who fail to respond to the first dose.

Adults with no evidence of immunity (evidence of immunity is defined as documented receipt of 1 dose [2 doses 4 weeks apart if high risk] of live measles virus-containing vaccine, laboratory evidence of immunity or laboratory confirmation of disease, or birth before 1957) should get 1 dose of MMR vaccine unless the adult is in a high-risk group. High-risk people need 2 doses and include school-age children, healthcare personnel, international travelers, and students attending post-high school educational institutions.

Storage

Priorx should be stored at 2° to 8°C (36° to 46°F). Do not freeze. Product which has been exposed to freezing should not be used. Do not use after the expiration date shown on the label.

How Priorix is Supplied

PRIORIX is supplied in a box (NDC 58160-824-15) containing:

- 10 single-dose vials of lyophilized antigen component
- 10 single-dose prefilled ungraduated syringes of sterile water diluent (packaged without needles)

Philadelphia Department of Public Health - Division of Disease Control - Immunization Program
1101 Market St. Floor 12, Philadelphia, PA, 19107 | **vax.phila.gov** | **vaccines@phila.gov** | December 2022

New VFC & VFAAR Vaccine Available
Priorix

Administration

Priorix must be reconstituted before administration. Reconstitute the Lyophilized Antigen Component, Live only with the accompanying Sterile Water Diluent Component to form Priorix. The reconstituted vaccine should be a clear peach to fuchsia, pink-colored suspension.



Figure 1
Hold the prefilled syringe by the barrel and unscrew the syringe cap by twisting it counter-clockwise. Align the needle to the axis of the syringe and attached by gently connecting the needle bub into the Luer Lock Adapter (LLA) and rotate a quarter turn clockwise until you feel it lock.



Figure 2
Cleanse the vial stopper. Transfer the entire contents of the prefilled syringe into the lyophilized antigen component vial.

Figure 3
Shake the vial well until the powder is completely dissolved. Do not invert the vial while shaking.

Figure 4
After reconstitution, **withdraw the entire contents** of the reconstituted vaccine into the same syringe and after changing the needle, administer **subcutaneously**.

Inspect the syringe for particulate matter and discoloration prior to administration. **If either of these conditions exist, the product should not be administered.**

Administer a single 0.5 mL dose of Priorix subcutaneously immediately after reconstitution.

Philadelphia Department of Public Health - Division of Disease Control - Immunization Program
1101 Market St. Floor 12, Philadelphia, PA, 19107 | **vax.phila.gov** | **vaccines@phila.gov** | December 2022

Department of Public Health
CITY OF PHILADELPHIA

New VFC & VFAAR Vaccine Available
Priorix

Ordering and Billing

Priorix will be available for ordering through the PhilaVax IIS as of, Tuesday, January 3, 2022.

VFC and VFAAR providers must decide whether they will order MMR II or Priorix going forward. Scan the adjacent QR code, or use this link, to complete a survey to notify our program your site preference. We will review each site's submission and reach out with next steps.

We recommend that sites that are part of a system or are affiliated use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

TAKE OUR SURVEY!

Resources

MMWR

https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7146a1-H.pdf

Priorix package insert

https://www.fda.gov/media/158941/download

Immunize.org

https://www.immunize.org/vis/vis_mmr.asp

Vaccine Information Statement (VIS)

https://www.immunize.org/askexperts/experts_mmr.asp

Philadelphia Department of Public Health - Division of Disease Control - Immunization Program
1101 Market St. Floor 12, Philadelphia, PA, 19107 | **vax.phila.gov** | **vaccines@phila.gov** | December 2022

Department of Public Health CITY OF PHILADELPHIA